In addition, we find that S100A4 was expressed in all progressing melanoma and non-small cell lung cancer BMs as well as being independently associated with time to intracranial progression in breast cancer – where patients had the longest OS time – but not in lung cancer, where patients were less likely to die from their brain disease. Here, S100A4 is linked to breast carcinoma.